Category: Antibiotics

Clostridioides difficile (C. diff) infection (CDI) is the most common cause of healthcare-associated infections in the United States. This raises the question for clinicians: in the context of severe infections, does meropenem cover C diff?

Amoxicillin is one of the most widely prescribed antibiotics worldwide, but its use is not universal, especially for those with a history of allergic reactions. Knowing what are the contraindications of amoxicillin is critical for preventing serious and potentially life-threatening side effects. This guide explores the key factors that can prevent a patient from safely taking this common medication.

In 2018, the FDA updated its warning for fluoroquinolone antibiotics, including levofloxacin, emphasizing the risk of serious side effects that can occur, including tendon rupture and permanent nerve damage. This serious potential for harm means that specific individuals, particularly those with pre-existing conditions, should avoid levofloxacin unless absolutely necessary.

First approved by the FDA in 1985, the brand name for PRIMAXIN is actually the brand name itself, but its generic name is the combination antibiotic imipenem/cilastatin. This potent medication is critical for treating severe bacterial infections by combining two powerful components that work together to kill a wide range of bacteria.

Linezolid represents the first new class of antibiotics in over 35 years, making its debut in 2000. But **what is special about linezolid** is not just its novelty but its unique mechanism of action and efficacy against difficult-to-treat, drug-resistant gram-positive infections, including MRSA and VRE.

Antibiotics like cephalosporins are a cornerstone of modern medicine, with 116 prescriptions per 1,000 people in the US in 2024. This article explores the question, 'What is TEVA Cephalexin used to treat?', detailing its role in combating specific bacterial infections.

According to the Centers for Disease Control and Prevention (CDC), *Acinetobacter baumannii* is a serious and increasingly common cause of healthcare-associated infections worldwide. As a Gram-negative bacterium, *Acinetobacter* is inherently resistant to the glycopeptide antibiotic vancomycin, meaning Vanco does not cover Acinetobacter infections.

Approximately one-third of the population carries *Staphylococcus aureus* (staph) in their nose without becoming sick. When this strain is methicillin-resistant, it becomes MRSA nasal colonization, which is addressed through a process called decolonization.

Meropenem is a powerful, broad-spectrum carbapenem antibiotic used for serious bacterial infections. While it does provide coverage against methicillin-sensitive Staphylococcus aureus (MSSA), its use must be carefully considered because more targeted and narrower-spectrum agents are typically preferred for treating this specific pathogen.

While amoxicillin remains a widely prescribed frontline antibiotic for respiratory infections, its effectiveness against *Streptococcus pneumoniae* (pneumococcus) is increasingly challenged by rising antibiotic resistance. This article explores the critical question, **does amoxicillin cover pneumococcus**, and explains the complex factors influencing treatment outcomes.